Search for Clinical Trial Results
Adenoma - 646 Studies Found
Status | Study |
Recruiting |
Study Name: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors Condition: Gastro-entero-pancreatic Neuroendocrine Tumors Date: 2016-04-07 Interventions:
|
Not yet recruiting |
Study Name: Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib Condition: Pancreatic Neuroendocrine Tumour Metastatic Date: 2016-03-16 Interventions: Drug: Sunitinib Sunitinib 37.5 mg/day |
Not yet recruiting |
Study Name: Pancreatic Neuroendocrine Tumor:Factor of Surgery Influencing Survival Condition: Pancreatic Neuroendocrine Tumor Date: 2015-11-30 Interventions: Procedure: pancreatectomy Remove the pancreatic neuroendocrine tumor by surgery |
Recruiting |
Study Name: Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Condition: Neuroendocrine Tumors Date: 2015-10-26 Interventions:
|
Recruiting |
Study Name: Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Condition:
Date: 2015-10-12 Interventions: Drug: Ibrutinib Ibrutinib will be administered orally once daily and each cycle will be defined as 4 wee |
Recruiting |
Study Name: Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors Condition: Neuroendocrine Tumors Date: 2015-06-16 Interventions:
|
Completed |
Study Name: An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms Condition: Pancreatic Endocrine Neoplasms Date: 2015-03-23 |
Recruiting |
Study Name: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus Condition: Pancreatic Neuroendocrine Tumour Metastatic Date: 2014-06-17 Interventions: Drug: Everolimus 10 mg daily everolimus is a recently approved mTOR inhibitor in advanced progressing we |
Recruiting |
Study Name: A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Condition: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours Date: 2014-09-23 Interventions:
|
Recruiting |
Study Name: The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors Condition: Pancreatic Neuroendocrine Tumors Date: 2014-10-15 Interventions: Drug: sunitinib subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg on |